GSMP Pharmaceutical Clinical Trials - Phase 2
Mission Specific Working Group (MSWG) WR – 19-139

**Milestone deliverables**

- **Project approved**
  - April ’19
  - Seated group

- **Requirements**
  - October ‘19
  - Com Rev & eBallot

- **Draft standard**
  - February ‘20
  - Com Rev & eBallot
  - IP review
  - BCS and MB

- **Publication**
  - *February ‘20
  - GS1 website

**Completed last 30 days**

- Resolving comments from community review with chairs and submitter
- On the 05 Feb call the chairs motioned and the team agreed to give a week to review the guideline as a clean version and then motion on the 13 Feb team call

**Next steps**

- Complete review and Motion guideline to eBallot on the 13 February call

**Risks and Issues**

- With the motion on the 13 February team call, the ratification will not take place until the first week of March which is one week late

**Project Description**

Phase 2 – Electronic Messaging

Phase 1 - Develop a GS1 standard and/or guideline that would detail the best practice approach to implementation of GS1 standards for Electronic Communications in the pharmaceutical clinical trial supply chain. This could include EDI and/or EPCIS

**Deliverable/Objective**

- Develop a GS1 standard and/or guideline that would detail the best practice approach to implementation of GS1 standards for Electronic Communications in the pharmaceutical clinical trial supply chain

**Company participation**

<table>
<thead>
<tr>
<th></th>
<th>Actual roster</th>
<th>Required roster</th>
<th>Minimum votes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>15</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Hospital</td>
<td>4</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>MO’s</td>
<td>18</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Other</td>
<td>14</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Stakeholders**

- LT Sponsor: Marianne Timmons
- SDL: Greg Rowe
- IE/Sol Liaison: Tania Snioch
- SME: Tania Snioch / Jean-Luc Champion
- AG Liaison: Henri Barthel

**Legend**

- G: On schedule
- Y: Minor Risk/-10% behind schedule
- R: Significant risk/10%+ behind schedule
- C: Complete

Update for 1 February 2020